Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies
Posted:
Millions of people with atopic dermatitis cope with both seen and unseen burdens of the disease. Discover more about important new clinical trial results and how Lilly is helping to improve care and understanding of this disease here.
Waystar has signed a definitive agreement to acquire Iodine Software, a $1.25 billion deal that seeks to empower healthcare payments with more AI capabilities.
Read more here.
Doctors will be able to prescribe a new treatment for people with inflammatory bowel disease (IBD), after the UK medicines watchdog approved guselkumab (Tremfya) for use on the NHS.
Read more here.